微創醫療(00853.HK):心脈醫療前兩月營收同比增35%至1.87億元左右
格隆匯3月16日丨微創醫療(00853.HK)公佈,心脈醫療(公司持有心脈醫療科技已發行股本約46.34%)公佈關於2022年1至2月主要經營數據,2022年1至2月,心脈醫療按照既定戰略有序開展各項業務,產品銷售勢頭良好,在去年同期基數較高且國內新冠疫情仍有反覆的情況下,營業收入繼續保持較快的增長。經心脈醫療初步核算,2022年1至2月,實現營業收入1.87億元人民幣左右,較去年同期同比增長35%左右。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.